Invion (ASX:IVX) — Material Events
ASX:IVX · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Invion Secures $2M Korean Grant, Expands Photosoft License, Raises $1.3MMedium
Invion secures $2M Korean grant, expands Photosoft license, raises $1.3M convertible notes
30 Jan 2026
·Quarterly Activity and Appendix 4C Cash Flow Report
·85
Invion Secures Exclusive Global License for Photosoft™ Across Multiple DiseasesMedium
Invion Secures Exclusive Global License for Photosoft™ Technology Across Multiple Indications
3 Dec 2025
·License Agreement Announcement
·85
Invion Expands Skin Cancer Trial to Basal Cell Carcinoma After Positive Safety and Efficacy SignalsMedium
Invion expands skin cancer trial to Basal Cell Carcinoma after positive safety and efficacy signals
21 Apr 2026
·Clinical Trial Update
·85
FDA Grants Orphan Drug Status to Invion’s INV043 for Anal CancerMedium
FDA Grants Orphan Drug Status to Invion's INV043 for Anal Cancer
20 Aug 2025
·Regulatory Announcement
·85
Invion Clinches FDA Orphan Drug Status, Raises $1.8M, Advances Cancer TrialsMedium
Invion secures FDA Orphan Drug Designation, raises $1.8M, advances cancer trials and animal health collaboration
31 Oct 2025
·Activity Report and Appendix 4C
·85
Invion Reveals FDA Orphan Drug Nod Behind Surge in SharesHigh
Invion discloses FDA Orphan Drug Designation for lead cancer drug following ASX price query
20 Aug 2025
·Response to Price Query
·Unexpected
·85
Invion and Hanlim Secure $2M Boost for Oesophageal Cancer Therapy TrialsMedium
Invion secures A$2M non-dilutive funding for oesophageal cancer preclinical program with Hanlim and South Korean government support
23 Dec 2025
·ASX Announcement
·80
Invion Reports $8.8M Loss Amid Clinical Progress and Funding EffortsMedium
Invion Limited reports $8.8M loss, advances clinical trials, raises $2M, faces going concern uncertainty
27 Aug 2025
·Annual Report
·75
Invion Secures $1.3M to Accelerate Cancer Trials with CEO Leading the ChargeMedium
Invion raises $1.3M via convertible notes to fund cancer clinical trials with CEO and major shareholder as cornerstone investors
30 Jan 2026
·Capital Raising
·75
Invion Advances Cancer Trials with $20K Grant and $1M Capital RaiseMedium
Invion advances cancer trials, secures grant, and raises $1M via Loyalty Option Offer
31 July 2025
·Activity Report and Appendix 4C
·75
Invion Confirms Prompt Disclosure of FDA Orphan Drug Status for Anal CancerMedium
Invion confirms timely disclosure of FDA Orphan Drug Designation for anal cancer treatment
28 Aug 2025
·ASX Aware Letter Response
·75
Invion Expands Photosoft Platform to Target $16.7B Wet AMD MarketMedium
Invion partners with SANGMYUNG to advance Photosoft technology for wet AMD treatment
19 May 2026
·Collaboration Agreement
·75
Invion and Protect Animal Health Team Up to Tackle Pet Cancer with PhotosoftMedium
Invion and Protect Animal Health collaborate to develop Photosoft cancer therapy for pets
21 Oct 2025
·Collaboration Agreement Announcement
·75
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Invion (ASX:IVX) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026
31 Jan 2026